Condition: B-ALL · Leukemia · Sponsor: ImmunityBio, Inc.
This is a phase 1, open-label study to evaluate the safety and efficacy of CD19 t-haNK in patients with B-cell acute lymphoblastic leukemia. Up to 10 patients will receive at least 1 dose of study drug.
This description comes directly from the study's public registry record.
Kayleigh Russell · 424-539-2412 · kayleigh.russell@immunitybio.com
Mark Nelson · mark.nelson@immunitybio.com
Always discuss trial participation with your own doctor first.
| Dr Jackie Thomson Inc | Johannesburg, South Africa | Recruiting |
| Alberts Cellular Therapy | Pretoria, South Africa | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07556757